BTK: Bruton’s tyrosine kinase (BTK) is an essential component of the B-cell receptor (BCR) signaling pathway that regulates the survival, activation, proliferation, and differentiation of B lymphocytes. The first BTK inhibitor, Ibrutinib, was approved by FDA for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. Through structure-guided approach, EBI discovered two structurally distinct, potent and selective BTK inhibitors, EBI-1266/1459 (SHR-1459/1266). EBI-1459 is currently in clinical development in Asia and is also licensed to TG Therapeutics for development outside Asia.